Wolfe Research initiated coverage of Krystal Biotech (KRYS) with a Peer Perform rating and no price target Krystal is “performing well” commercially with Vyjuvek and the firm thinks shares are fairly valued, but it adds that it is “cautiously optimistic” heading into the company’s key catalysts this year that include KB801/803 in eye conditions and KB407 in cystic fibrosis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech price target raised to $325 from $318 at BofA
- Krystal Biotech price target raised to $284 from $224 at Guggenheim
- Krystal Biotech price target raised to $323 from $220 at Chardan
- Buy Rating on Krystal Biotech Driven by Vyjuvek’s Global Momentum and Upside from Enhanced NK and Corneal Abrasion Pipeline
- Krystal Biotech: Transitioning to Global Growth as De‑Risked HSV‑1 Gene Therapy Platform Advances Toward Pivotal Stages